Setmelanotide
Setmelanotide targets the MC4R receptor in your hypothalamus — the same melanocortin system that PT-141 activates for sexual arousal. Its primary action is silencing the hunger signals that drive genetic obesity, but because it hits MC4R, increased sexual desire is a documented side effect. FDA-approved for rare genetic obesities.
About Setmelanotide
Setmelanotide was developed by Rhythm Pharmaceuticals and approved for treatment of obesity due to POMC, PCSK1, or LEPR deficiency. Unlike previous MC4R agonists, setmelanotide demonstrates improved selectivity for MC4R over MC1R, MC3R, and MC5R, reducing off-target melanocortin effects. Research explores its mechanism through hypothalamic MC4R activation, downstream effects on appetite-regulating neuropeptides (AgRP, NPY, POMC), and energy expenditure modulation. It serves as a critical research tool for understanding the melanocortin obesity pathway and genetic disorders of energy balance.
Full Research Monograph — 4 PubMed CitationsYou May Also Consider
PT-141
10mgThe sex drive peptide — works directly in your brain to ignite genuine sexual desire and arousal in both men and women. FDA-approved mechanism. This is the one everyone's talking about.
- Directly increases sexual desire and arousal in both men AND women
- Works through the brain — not blood flow — for genuine desire, not just mechanics
The weight loss revolution — the same molecule in Ozempic that helps millions lose 15-20% of body weight by silencing food cravings and resetting appetite at the brain level.
- Lose 15-20% of body weight without willpower or starvation
- Completely eliminates food noise and constant cravings
Retatrutide 12mg
12mgThe most powerful weight loss compound ever studied — triple-receptor agonist that achieved 24% body weight loss in trials, outperforming semaglutide by hitting THREE metabolic pathways.
- Triple-action weight loss — targets GLP-1, GIP, AND glucagon receptors
- 24% body weight loss in trials — MORE than semaglutide